



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/917,181	09/917,181 07/26/2001		Felix Theeuwes	DURE-023	9651
24353	7590	06/15/2004	EXAMI		INER
		D & FRANCIS LL	LAM, ANN Y		
200 MIDDLI SUITE 200	EFIELD	КD	ART UNIT	PAPER NUMBER	
MENLO PAI	RK, CA	94025	1641		
				DATE MAILED: 06/15/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	tion No.	Applicant(s)
		09/917,	181	THEEUWES ET AL.
Office Action Summary		Examine		Art Unit
		Ann Y. L	.am	1641
Ti	he MAILING DATE of this commun	ication appears on ti	he cover sheet with	the correspondence address
A SHOR' THE MAI - Extension after SIX ( - If the period - If NO period - Failure to Any reply	TENED STATUTORY PERIOD FOR ILLING DATE OF THIS COMMUNI IS of time may be available under the provisions (6) MONTHS from the mailing date of this commod for reply specified above, the maximum star reply within the set or extended period for reply received by the Office later than three months a tent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no elunication. 0) days, a reply within the statutory period will apply and will, by statute, cause the apply and will.	event, however, may a reply atutory minimum of thirty (3 will expire SIX (6) MONTHS oplication to become ABANI	be timely filed  0) days will be considered timely.  3 from the mailing date of this communication.  DONED (35 U.S.C. § 133).
Status				
2a)∐ Thi 3)∐ Sin	sponsive to communication(s) file is action is <b>FINAL</b> .  In a cethis application is in condition is sed in accordance with the practic	2b)⊠ This action is for allowance excep	non-final. ot for formal matters	
Disposition	of Claims			
4a) 5)⊠ Cla 6)⊠ Cla 7)⊠ Cla	tim(s) <u>1,2,4, 6-14,17-22,24,25 and</u> Of the above claim(s) is/ar tim(s) <u>25 and 32</u> is/are allowed. tim(s) <u>1,2,4,6-13,18-22,24,29 and</u> tim(s) <u>14,17 and 31</u> is/are objected tim(s) are subject to restrict	re withdrawn from co 30 is/are rejected. d to.	onsideration.	1.
Application l	Papers			
10)□ The App Rep	specification is objected to by the drawing(s) filed on is/are: plicant may not request that any objected to placement drawing sheet(s) including oath or declaration is objected to	a) accepted or b tion to the drawing(s) the correction is requi	be held in abeyance. red if the drawing(s) is	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).
Priority unde	er 35 U.S.C. § 119			
a)	nowledgment is made of a claim full b) Some * c) None of: Certified copies of the priority of Copies of the certified copies of application from the Internation the attached detailed Office action	documents have bed documents have bed of the priority docum nal Bureau (PCT Ru	en received. en received in Appli ents have been rec le 17.2(a)).	ication No reived in this National Stage
Attachment(s)				
2) Notice of [3] Information	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PT n Disclosure Statement(s) (PTO-1449 or F s)/Mail Date		Paper No(s)/Ma	nary (PTO-413) all Date nal Patent Application (PTO-152)

Art Unit: 1641

### **DETAILED ACTION**

### **Drawings**

The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the two outlets (claim 17) and two lumens (claim 18) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. (It is not clear in the drawings and in the specification where the two outlets and two lumens are located. For example, specification, page 37, line 4, states that outlet is located at (24), and Figures 8A and 8B, shows only one reference number (24).)

Corrected drawing sheets are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. The replacement sheet(s) should be labeled "Replacement Sheet" in the page header (as per 37 CFR 1.84(c)) so as not to obstruct any portion of the drawing figures. If the changes are not accepted by the examiner, the applicant will be notified and informed of

Art Unit: 1641

any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 4, 6-13, 18-20, 22, 24 and 29 are rejected under 35 U.S.C. 102(b) as being anticipated by Wolinsky et al. 5,087,244.

Wolinksy discloses an elongate body (10) comprising a proximal end defining an inlet, and a distal end defining an outlet, the elongate body defining a lumen in the elongate body, said lumen extending between the proximal and distal ends;

and a diffuser element (16) operatively associated with the elongate body so as to define a diffusion space (i.e., space within element 16), wherein the elongate body distal end outlet is disposed in and in fluid communication with the diffusion space, and wherein the diffusion space is drug-permeable and water-permeable to provide for dilution of a drug in the diffusion space. (The device is capable of providing for dilution of a drug since, for example, if fluid pressure from the source of medicine is discontinued, some fluid from the patient's body may entered element 16.)

Art Unit: 1641

As to claim 2, the diffuser element (16) comprises a semipermeable membrane, a microporous membrane or an ion exchange membrane. (The element 16 has minute holes (29) that is considered semipermeable since it allows through medicine or fluid but not substances that are larger than the size of the holes.)

As to claim 4, the distal outlet of the elongate body is defined by an exit orifice (20) of a drug delivery device and the diffuser element (16) is considered a cap in which the exit orifice is disposed since element (16) is at the distal end of elongate body.

As to claim 6, the diffusion space is defined by an outer wall of the elongate body (10) and an inner wall of the diffuser element (16), (see lumen at and near 20, Figure 2.)

As to claim 7, said diffuser element (16) envelops at least a portion of said elongate body (10), see Figure 2.

As to claim 8, the diffuser element is microporous, (column 4, lines 1-2.)

As to claim 9, the diffuser element is considered a dense membrane, (see column 5, lines 22-24, and lines 49-51.)

As to claim 10, the diffuser element is an ion-exchange membrane, (column 4, lines 1-2) since the holes (29) are capable of allowing an exchange of ions.

As to claim 11, said diffuser element distal end extends distally beyond the elongate body distal end, see Figure 2.

As to claim 12, the diffuser element distal is ring-shaped element, see Figure 2.

As to claim 13, the diffuser element is selectively permeable to water (column 4, lines 3-5.)

Art Unit: 1641

As to claim 18, the elongate body defines at least two lumens within the elongate body (18 and 26).

As to claims 19 and 24, the elongate body lumen is adapted for delivery of agent at a low volume rate, (column 4, lines 19-24.)

As to claim 20, the device is operably attached to a drug delivery reservoir, (column 5, lines 25-26.)

As to claim 22, the drug is capable of being delivered in microliter or submicroliter quantities per day (column 4, lines 3-5.)

As to claim 24, the device is capable of allowing formulation to be introduced into the inlet at a low volume rate (column 5, lines 25-28.)

As to claim 29, the diffuser element comprises a polymeric film, (column 3, lines 47-49.)

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 30 is rejected under 35 U.S.C. 103(a) as being unpatentable over Wolinsky et al., 5,087,244.

Art Unit: 1641

Wolinsky discloses the invention substantially as claimed (see above).

Wolinsky discloses that the "aggregate flow area defined by the holes 29 is selected so that under the general range of inflation pressures expected, the liquid flow through the holes will be very low, weeping in nature, and will not exceed a predetermined maximum flow rate in atmosphere. Although the foregoing configuration of holes is believed to be satisfactory for a wide range, and possibly most, if not all, medications or drugs to be delivered, it is possible that certain medications or drubs [believed by Examiner to be a misspelling for 'drugs'] may have viscosity and flow characteristics as might require modifications to the holes" (column 4, lines 19-29.)

Wolinsky however does not teach that the diffuser element has a Diffusion Coefficient value in the range between 4.1 x 10-6 and 3.3 x 10-5 ug/cm/sec. However, it would have been obvious to form the diffuser element in which the holes' size and spacing is selected such that it has the specific Diffusion Coefficient as claimed, since Wolinsky teaches that medications may have viscosity and flow characteristics that might require modifications to the holes.

Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over Wolinsky et al., 5,087,244, in view of Aoki et al., 6,113,915.

Wolinsky discloses the invention substantially as claimed (see above). Wolinsky teaches a catheter for delivery drugs to a body member having a lumen (column 2, lines 49-53.) However, Wolinksky does not disclose that the catheter contains Baclofen.

Art Unit: 1641

Aoki teaches use of a small catheter to deliver baclofen to treat spasticity since the intrathecal space is generally wide enough to accommodate a small catheter (column 2, lines 41-45.) It would have been obvious to use the Wolinsky catheter to deliver baclofen to treat spasticity since the intrathecal space is generally wide enough to accommodate a small catheter, as taught by Aoki.

# Response to Arguments

Applicant's arguments with respect to the above claims have been considered but are moot in view of the new ground(s) of rejection.

# Allowable Subject Matter

Claims 25 and 32 are allowed.

Claims 14, 17, and 31 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Y. Lam whose telephone number is 571-272-0822. The examiner can normally be reached on M-Sat 11-6:00.

Art Unit: 1641

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A.L. (

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800 / 647

Christina L. Chi